Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 10/20 | 0.68 |
| ▸ | THRB | P10828 | 10/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | RARB | P10826 | 1/20 | 0.61 |
| ▸ | PLK1 | P53350 | 1/20 | 0.61 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.60 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089476 | 0.94 | THRA (0.70) | THRATHRBL3MBTL1RARBPLK1 | |
| SCHEMBL15960542 | 0.93 | THRA (0.79) | THRATHRBRARBHAO1ALDH1A1 | |
| SCHEMBL12600892 | 0.87 | NPC1 (0.66) | THRATHRBL3MBTL1HSD17B3HAO1 | |
| SCHEMBL3234253 | 0.87 | THRA (0.66) | THRATHRBL3MBTL1RARBPLK1 | |
| SCHEMBL7813104 | 0.87 | L3MBTL1 (0.81) | THRATHRBL3MBTL1RARBPLK1 | |
| SCHEMBL27352122 | 0.87 | THRA (0.62) | THRATHRBL3MBTL1RARBPLK1 | |
| SCHEMBL7633932 | 0.86 | PLK1 (0.68) | THRATHRBRARBPLK1HAO1 | |
| SCHEMBL10031544 | 0.86 | THRA (0.64) | THRATHRBRARBPLK1HAO1 | |
| SCHEMBL28013341 | 0.86 | THRA (0.64) | THRATHRBL3MBTL1RARBPLK1 | |
| SCHEMBL8971794 | 0.86 | THRA (0.60) | THRATHRBL3MBTL1RARBHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175061-B2 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-8129545-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129545-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7982048-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982048-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110144017-A1 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20110021633-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS, INC. | 2011-01-27 | — | — | US | disclosed |
| US-7132537-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-7041829-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1355638-B1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20060069259-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2006-03-30 | — | — | US | disclosed |
| US-20050096279-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6664420-B2 | For therapy of hypertension, type 2 insulin-resistant diabetes mellitus, ecalmpsia and preeclampsia | MAGNESIUM DIAGNOSTICS, INC. | 2003-12-16 | — | — | US | disclosed |
| EP-1355638-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | Magnesium Diagnostics, Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030040625-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2003-02-27 | — | — | US | disclosed |
| US-6455734-B1 | ADMINISTERING PHENYLGLYCINAMIDE(N-2,4-DIAMYLPENTANOIC ACID AMIDE) AS HYPOTENSIVE AGENTS FOR PROPHYLAXIS OF INSULIN RESISTANCE, ECLAMPSIA AND SENSITIVITY TO BLOOD METAL CONCENTRATIONS | MAGNESIUM DIAGNOSTICS, INC. | 2002-09-24 | — | — | US | disclosed |
| WO-2002011714-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040625-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | ECE1, PLPBP, ECE2 | THRA 1040/4885THRB 350/4885L3MBTL1 288/4885 |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | THRA 1022/4885THRB 366/4885L3MBTL1 315/4885 |
| US-20110021633-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | THRA 1022/4885THRB 366/4885L3MBTL1 315/4885 |
| US-20060069259-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | ECE1, PLPBP, ECE2 | THRA 1040/4885THRB 350/4885L3MBTL1 288/4885 |
| US-20050096279-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | THRA 1022/4885THRB 366/4885L3MBTL1 315/4885 |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | PLPBP, ECE1, MCU | THRA 1022/4885THRB 366/4885L3MBTL1 315/4885 |
| US-20110144017-A1 | Protein conjugates and methods for their preparation | PTMS, DNPEP, ANPEP | THRA 1922/4885THRB 3163/4885L3MBTL1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.